Latest news
01.10.2020
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...
15.07.2020
DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-...
17.06.2020
Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
Press Coverage
12.05.2020
Cdiff Foundation | A New Parenteral Treatment for a Severe C. difficile Infection
"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla Join us with our two guests: Dr Yannick Pletan...
08.05.2020
Biotech & Finance | Alexis Rideau, arrive chez Deinove avec son réseau industriel et académique de pointe
C’est une nouvelle aventure pour Alexis Rideau, qui occupe depuis cette semaine la fonction de directeur général délégué de Deinove...
06.05.2020
La Tribune | Deinove recrute Alexis Rideau, nouveau DG délégué
Deinove, société montpelliéraine de biotechnologie développant des antibiotiques novateurs et des actifs biosourcés pour la cosmétique et...